Amgen prostate cancer：AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA ...

AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA ...

2022年8月8日—Phase1TarlatamabStudyShowedEncouragingAntitumorActivityWithMedianDurationofResponseof13MonthsinSmallCellLungCancer.。其他文章還包含有：「TargetingProstate」、「TargetingSTEAP1」、「Amgenstopscancertrial」、「AmgenAxesProstateCancerDrug」、「AMGENTOPRESENTNEWRESEARCHFROM...」、「ProstateCancerDiseaseStateEducationDeck」、「Amgencutsprostatecancerdrugin$650Mwritedown...」、「ThreeTh...

查看更多離開網站

Provide From Google

Targeting Prostate

https://www.amgenoncology.com

Therefore, PSMA is an attractive target for the treatment of prostate cancer and potentially other solid tumors.2-4. Learn more about modalities targeting PSMA:

Provide From Google

Targeting STEAP1

https://www.amgenoncology.com

Discover why STEAP1 (six-transmembrane epithelial antigen of prostate 1) is a therapeutic target and overexpressed in prostate cancer.

Provide From Google

Amgen stops cancer trial

https://www.fiercebiotech.com

Amgen is testing tarlatamab in a form of prostate cancer and has another mCRPC project on the go. ... AmgenTeneobiobispecific antibodiesprostate ...

Provide From Google

Amgen Axes Prostate Cancer Drug

https://www.biospace.com

The prostate cancer drug was acquired as part of a $900 million upfront buy of Teneobio in 2021. In its reprioritization decision, Amgen said it ...

Provide From Google

AMGEN TO PRESENT NEW RESEARCH FROM ...

https://www.prnewswire.com

These results further justify exploration of this modality as a potential therapy for prostate cancer. Dose expansion and optimization are ...

Provide From Google

Prostate Cancer Disease State Education Deck

https://www.amgenoncology.com

*Amgen is investigating a number of T-cell engaging platforms, including ... mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific ...

Provide From Google